Therapeutics Company Secures $3M Department of Defense Award For Pediatric Brain Cancer Trials

In an unprecedented move that signals a new era for cancer treatment, Plus Therapeutics, Inc., a trailblazer in the development of targeted radiotherapeutics, has been awarded a $3 million grant by the Department of Defense (DoD) through its Congressionally Directed Medical Research Programs (CDMRP). This substantial funding, set to kick off in Q3 2024, is earmarked for the expansion of clinical trials focused on pediatric brain cancer, offering a glimmer of hope for countless families and medical professionals grappling with this devastating diagnosis. $Plus Therapeutics(PSTV.US)$